Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients.

Zaira MaraiaTony MazzoniMarco Bruno Luigi RocchiDenise FelicianiMaria Chiara RomaniGiovanna AcciarriStefania RafaianiIsidoro Mazzoni

Published in: Journal of personalized medicine (2022)

The results of this analysis support the use of biological drugs and justify further research investigating the association of these biological therapies with COVID-19 outcomes.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
drug induced
prognostic factors
type diabetes
skeletal muscle